Cagrilintide Semaglutide Blend 5mg 5mg Heritage Labs USA Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta Analysis Journal of Clinical Question nejm Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension